Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer.
Kavya RamkumarAzusa TanimotoCarminia Maria Della CorteC Allison StewartQi WangLi ShenRobert J CardnellJing WangUrszula M PolanskaCourtney L AndersenJamal SaehJ Elizabeth PeaseJon TraversGiulia FabbriCarl M GayJelena UrosevicLauren Averett ByersPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
BCL2 inhibition overcomes intrinsic resistance and enhances sensitivity to AURKB inhibition in SCLC preclinical models.